indication
as of 2026-07-01Schizotypal Personality Disorder
Competitive landscape projected to sertraline-primary’s launch window
Competitive set
2
2 approved · 0 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
30 events
2020
2024
2028
2032
2036
2040
today
sertraline-primary launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugCompleted
US-approved 1993 · RISPERDAL
—1 trial
Protection2042
drugTerminated
US-approved 2002 · ABILIFY
—1 trial
Protection2041
Market size
prevalence as a range, not a number